ARK Genomic Revolution ETF
ARKG

$27.23

2.02%

Market Cap: 1.45B

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

8.1% more ownership

Funds ownership: 28.83% [Q4 2023] → 36.94% (+8.1%) [Q1 2024]

2% less capital invested

Capital invested by funds: $618M [Q4 2023] → $605M (-$13.1M) [Q1 2024]

8% less funds holding

Funds holding: 288 [Q4 2023] → 265 (-23) [Q1 2024]

35% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 95

47% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 49

48% less call options, than puts

Call options by funds: $42.2M | Put options by funds: $80.8M

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 1 (-1) [Q1 2024]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ARKG.

See Analyst Rankings

Financial journalist opinion

ARKG: A Genomics Play But Active Isn't Adding Value

Genomics is rapidly advancing, shaping our understanding of health, disease, and life itself. Consider investing in the ARK Genomic Revolution ETF for exposure to leading genomics companies. ARKG's active management may not be outperforming compared to passive genomics ETFs like PBE, with potential regulatory and concentration risks.

ARKG: A Genomics Play But Active Isn't Adding Value

BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada

TORONTO--(BUSINESS WIRE)---- $ARKG #Cboe--Cboe Canada is pleased to announce BMO has transferred three BMO mutual fund ETF series, trading under the symbols ARKK, ARKW, and ARKG to Cboe Canada.

BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada

The Motley Fool

Here's How Cathie Wood (Almost) Completely Missed the Boat on Artificial Intelligence (AI) -- and the Simplest Way You Can Avoid Making the Same Mistake

Despite touting growth themes in a growth-fueled market, ARK Invest's exchange-traded funds are noticeably trailing major benchmarks. Betting big on a few companies can lead to massively outsize gains or missed opportunities.

Here's How Cathie Wood (Almost) Completely Missed the Boat on Artificial Intelligence (AI) -- and the Simplest Way You Can Avoid Making the Same Mistake

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

The Motley Fool

3 Cathie Wood ETFs Just Hit 4-Month Lows. Are They Worth Buying Now?

There are better ways to approach innovation than the Ark Innovation ETF. The ARK Space Exploration & Innovation ETF is a balanced bet.

3 Cathie Wood ETFs Just Hit 4-Month Lows. Are They Worth Buying Now?

Zacks Investment Research

Time to Tap Healthcare ETFs on Nvidia's AI Ambition?

At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.

Time to Tap Healthcare ETFs on Nvidia's AI Ambition?

ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons

ARK Genomic Revolution ETF warrants a hold rating due to multiple roadblocks preventing solid returns, including underdeveloped technology, legal hurdles, and unresolved ethical dilemmas. ARKG has a relatively high expense ratio with no dividend yield, and its performance has significantly underperformed the S&P 500 Index. The fund's holdings are concentrated in the healthcare sector, with little overlap with other peer genomics-related funds.

ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons

3 Biotech ETFs Overdue for a Bounce

Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of course, to get a higher chance at outsized gains, one must also have a high risk tolerance and a long-enough investment horizon.

3 Biotech ETFs Overdue for a Bounce

Best Healthcare ETFs To Buy Now

The best healthcare ETFs patch investors into an area of the market that offers both defensive properties and long-term growth.

Best Healthcare ETFs To Buy Now

China-focused ETFs struggle amid fears of another regulatory ‘crackdown'

Hi! This week's ETF Wrap funds looks at China-focused funds that are struggling in 2024, with Clocktower's chief strategist Marko Papic providing his take on concerns tied to the country.

China-focused ETFs struggle amid fears of another regulatory ‘crackdown'

See News Rankings